# CA209-8Y8 (NCT03873402)

> A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

No report yet. It can be ordered.

- Indication: previously untreated intermediate/poor-risk advanced renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03873402
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Bristol-Myers Squibb
- Conditions: Renal Cell Carcinoma
- Interventions: Nivolumab; Ipilimumab; Ipilimumab placebo
- Enrollment: 437
- Primary outcome: Progression free survival (PFS) by blinded independent central review (BICR)
- Primary outcome: Objective response rate (ORR) by BICR

## Indexed commentary on CA209-8Y8 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=ca209-8y8-nct03873402